Evidence map›Paper›PMID 32695939›Full record

ArticleBioactive materials2020

A pretargeting nanoplatform for imaging and enhancing anti-inflammatory drug delivery.

Min Kyung Khang, Jun Zhou, Cynthia M Co, Shuxin Li, Liping Tang

Open access · goldAbstract read
In one paragraph

Article in Bioactive materials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Min Kyung KhangDepartment of Chemistry and Biochemistry, University of Texas at Arlington, 700 Planetarium Place, Chemistry Physics Building Room 130, Arlington, TX, 76019-0065, USA.
Jun ZhouDepartment of Bioengineering, University of Texas at Arlington, Engineering Research Building, Room 226, Box 19138, Arlington, TX, 76010, USA.
Cynthia M CoDepartment of Bioengineering, University of Texas at Arlington, Engineering Research Building, Room 226, Box 19138, Arlington, TX, 76010, USA.
Shuxin LiDepartment of Bioengineering, University of Texas at Arlington, Engineering Research Building, Room 226, Box 19138, Arlington, TX, 76010, USA.
Liping TangDepartment of Bioengineering, University of Texas at Arlington, Engineering Research Building, Room 226, Box 19138, Arlington, TX, 76010, USA.
The University of Texas at Arlington · US

Funding

Interdisciplinary Training in Nanotechnology for Cardiovascular and Lung Diseases in North TexasT32HL134613 · NHLBI · UNIVERSITY OF TEXAS ARLINGTON · PI NGUYEN, KYTAI TRUONG · 2017 to 2021
$1.1M
NHLBI NIH HHS T32 HL134613
6 · The paper itself

Abstract

This work details a newly developed "sandwich" nanoplatform via neutravidin-biotin system for the detection and treatment of inflammation. First, biotinylated- and folate-conjugated optical imaging micelles targeted activated macrophages via folate/folate receptor interactions. Second, multivalent neutravidin proteins in an optimal concentration accumulated on the biotinylated macrophages. Finally, biotinylated anti-inflammatory drug-loaded micelles delivered drugs effectively at the inflammatory sites via a highly specific neutravidin-biotin affinity. Both

Indexed as

BFMC, biotinylated- and folate-conjugated micelleBMC, biotinylated micelleDexamethasoneDex, DexamethasoneFMC, folate-conjugated micelleInflammatory responsesMacrophagesNeutravidin/biotin systemPolymeric micellesPretargeting

Identifiers

PMID32695939
PMCPMC7365982
OpenAlexW3042781490

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.